Phase II Clinical Trial of Neoadjuvant Treatment With Zolendronic Acid Plus Anthracycline and Taxane in Locally Advanced Breast Cancer

Trial Profile

Phase II Clinical Trial of Neoadjuvant Treatment With Zolendronic Acid Plus Anthracycline and Taxane in Locally Advanced Breast Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 12 May 2017

At a glance

  • Drugs Zoledronic acid (Primary) ; Cyclophosphamide; Docetaxel; Doxorubicin; Trastuzumab
  • Indications Breast cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms ZoNantax
  • Most Recent Events

    • 04 May 2017 Status changed from recruiting to completed.
    • 04 Mar 2013 The antineoplastic regimen was changed to include cyclophosphamide instead of fluorouracil, the duration of zolendronic acid was changed from from 6 to 8 cycles, and other durations were changed from 3 to 4 cycles, according to ClinicalTrials.gov.
    • 04 Mar 2013 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top